Open AccessTargeted‐cryosurgical ablation of the prostate with androgen deprivation therapy: quality of life in high‐risk prostate cancer patients
Author(s) -
Kang SeokHo,
Kim JinWook,
Bae JaeHyun,
Park HongSeok,
Moon DuGeon,
Yoon DuckKi,
Cheon Jun,
Kim JeJong
Publication year - 2006
Publication title -
asian journal of andrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.701
H-Index - 74
eISSN - 1745-7262
pISSN - 1008-682X
DOI - 10.1111/j.1745-7262.2006.00176.x
Subject(s) - medicine , prostate cancer , androgen deprivation therapy , quality of life (healthcare) , prostate , oncology , erectile dysfunction , urology , sexual dysfunction , cancer , gynecology , nursing
Aim : To present preliminary results on health‐related quality of life (QoL), prostate‐associated symptoms and therapeutic effects of targeted‐cryosurgical ablation of the prostate (TCSAP) with androgen deprivation therapy (ADT) in high‐risk prostate cancer (PCa) patients. Methods : Thirty‐four men with high‐risk PCa features underwent TCSAP, and ADT was added to improve the treatment outcomes. High‐risk parameters were defined as either prostate‐specific antigen (PSA) ≥ 10ng/mL, or Gleason score ≥ 8, or both. The Genito–Urinary Group of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire‐Core 30 (EORTC QLQ‐C30) with prostate‐cancer‐specific module (QLQ‐PR25) was used for evaluating morbidities and PSA levels were recorded every 3 months. PSA failure was defined as the inability to reach a nadir of 0.4 ng/mL or less. Results : Although it was not statistically significant, the global health status scores increased after TCSAP with ADT. The scores for five functional scales also became higher after treatment. The most prominent symptom after treatment was sexual dysfunction, followed by treatment‐related and irritative voiding symptoms. Conclusion : TCSAP with ADT appears to be minimally invasive with high QoL except for sexual dysfunction. Long‐term follow‐up of PSA data and survival is necessary before any conclusions can be made on the efficacy of this promising new therapeutic modality in the treatment of PCa.